CLL study tracks Long-Term survival after First-Line treatment

NCT ID NCT06792994

Recruiting now Knowledge-focused Sponsor: German CLL Study Group Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This observational study follows 2,000 people with chronic lymphocytic leukemia (CLL) who have completed first-line treatment in earlier clinical trials. Researchers will collect data from routine care to see how different treatment sequences affect overall survival, quality of life, and safety over time. The goal is to learn what factors help patients live longer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this study could help doctors understand which treatment sequences work best for long-term survival in CLL patients.
What could go wrong: This is an observational study, not a treatment trial, so it won't directly test new therapies. Results may take years and depend on real-world data quality.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC LYMPHOCYTIC LEUKEMIA

Contacts and locations

Locations

University Hospital Cologne
RECRUITING

Cologne, 50924, Germany
Universitätsklinikum Ulm
RECRUITING

Ulm, 89081, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.